Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Novo nordisk On Saturday, his pills for diabetes Rybelsus showed cardiovascular advantages during the late stage, opening the way to become a new treatment for people who live with diabetes and heart disease.
The tablet reduced the risk of cardiovascular death, heart attack and stroke by 14% compared to placebo after four years on average in patients with diabetes and heart disease, with or without chronic kidney disease. The Danish drug manufacturer presented the results on Rybelsus, which has already been approved for type 2 diabetes, in the annual scientific session of the American College of Cardiology in Chicago.
Novo Nordisk has already applied to the US and the EU to expand the resolution of the pills to include a reduction in the risk of serious cardiovascular complications, said Stephen Goff, the world chief of the company.
Rybelsus is a single oral blockbast diabetes of Novo Nordisk, which is taken once a week. Both treatments, as well as weekly weight injection, contain an active semaglutide ingredient.
In March 2024, Vegavi received a US permission to reduce the risk of major cardiovascular events in adults with cardiovascular disease and obese or overweight. But the data of the tablets presented on Saturday suggest that patients who are under to take injections, such as those who are afraid of needles, may soon access treatment more conveniently.
“We know that not everyone wants injections, whether it hurts or not, they want an oral medicine,” Goff CNBC said. “We suggest this option that you may have one or the other, depending on the fact that patients and healthcare providers consider it correct in this joint discussion.”
Data come as slate other drug manufacturers, including Eli Lily, Work on the development of oral GLP-1 for diabetes, weight loss and other conditions such as apnea.
In the third test, the phase studied just over 9,600 patients 50 years of age and older who received either Rybelsus or placebo, both at the top of their standard treatment mode, on average just under four years. Almost half of all patients received a medication called SGLT2 inhibitors, which are mainly used to reduce blood sugar in adults with type 2 diabetes, at some point during the test.
By the end of the trial, 12% of people who take Rables and 13.8% of those who occupy placebo survive cardiovascular death, heart attack or stroke. This is 14% of the total less risk among those who took Rybelsus.
Researchers note that the reduced risk is in line with the cardiovascular preferences observed in eight previous trials involving Injectable GLP-1, which include semaglutide and other popular medicines, according to the issue of the American College of Cardiology. GLP-1s imitate certain bowel hormones to think of appetite and regulate blood sugar, but also have other effects such as a decrease in inflammation.
Rybelsus helped reduce the risk of non-sided heart attacks by 26% compared to the placebo, which was the “major engine” of the overall risk of cardiovascular complications in the test, the release said. The tablet also cut the risk of non-sided strokes by 12% and cardiovascular death by 7% compared to placebo.
There was no significant difference between Rybelsus and placebo groups in renal function, the release is added. But the trial was “clearly” designed to study the cardiovascular rather than the benefits of kidney pills, Goff said.
Azizpic is there already approved For the treatment of chronic kidney disease in diabetes patients.
The most common side effects reported in the study were problems with the gastrointestinal tract such as nausea, diarrhea and constipation, which rarely made patients stop taking Rybelsus, the release said. These symptoms correspond to the side effect of injection semaglutide.
Similar results were noticed in all subgroups of patients – in age, gender and among people with different health conditions at the beginning of the trial, the release said.
Unlike their injection colleagues, Ribles should be taken on an empty stomach for at least 30 minutes before breakfast with a little water. Despite these requirements, the study proposes “assurance that patients were able to accept drugs by directed and repayment of cardiovascular care from this,” said Dr. Darren McGuayer, Professor of the South Western Medical Center and the first author of the study.
